Propranolol HCL-loaded liposomes for intranasal delivery : in vitro and ex vivo evaluation of optimized formulation using design of experiments
Aim: To develop a propranolol HCL-loaded liposomal nasal formulation for migraine prophylaxis. Materials & methods: Formulated the liposomes through thin layer hydration method and optimized via design of experiments (DOE). The prepared liposomes were characterized for particle size, zeta potential, PDI, drug entrapment and drug loading. Assessed for in vitro release kinetics, ex vivo permeability, histopathology and stability. Results: Optimized liposomes: 135.52 ± 5.87 nm, -19.9 ± 0.075 mV, 95.41 ± 0.05% entrapment, 43.37 ± 0.02% loading. Showed immediate (30.07 ± 2.09%) and sustained release (95.69 ± 4.58%) over 10 h. Enhanced permeation compared with controls; well-tolerated histopathologically. Conclusion: Liposomal formulation offers promise for intranasal propranolol HCL delivery in migraine prophylaxis, with stability under refrigeration.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Therapeutic delivery - 14(2023), 11 vom: 01. Nov., Seite 705-720 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kumar, Vishal [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9Y8NXQ24VQ |
|---|
| Anmerkungen: |
Date Completed 16.12.2023 Date Revised 09.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.4155/tde-2023-0044 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36505688X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36505688X | ||
| 003 | DE-627 | ||
| 005 | 20240209231958.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/tde-2023-0044 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1285.xml |
| 035 | |a (DE-627)NLM36505688X | ||
| 035 | |a (NLM)38014488 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kumar, Vishal |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Propranolol HCL-loaded liposomes for intranasal delivery |b in vitro and ex vivo evaluation of optimized formulation using design of experiments |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.12.2023 | ||
| 500 | |a Date Revised 09.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Aim: To develop a propranolol HCL-loaded liposomal nasal formulation for migraine prophylaxis. Materials & methods: Formulated the liposomes through thin layer hydration method and optimized via design of experiments (DOE). The prepared liposomes were characterized for particle size, zeta potential, PDI, drug entrapment and drug loading. Assessed for in vitro release kinetics, ex vivo permeability, histopathology and stability. Results: Optimized liposomes: 135.52 ± 5.87 nm, -19.9 ± 0.075 mV, 95.41 ± 0.05% entrapment, 43.37 ± 0.02% loading. Showed immediate (30.07 ± 2.09%) and sustained release (95.69 ± 4.58%) over 10 h. Enhanced permeation compared with controls; well-tolerated histopathologically. Conclusion: Liposomal formulation offers promise for intranasal propranolol HCL delivery in migraine prophylaxis, with stability under refrigeration | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a DOE | |
| 650 | 4 | |a liposome | |
| 650 | 4 | |a migraine | |
| 650 | 4 | |a nose to brain delivery | |
| 650 | 4 | |a particle size | |
| 650 | 4 | |a propranolol HCL | |
| 650 | 7 | |a Liposomes |2 NLM | |
| 650 | 7 | |a Propranolol |2 NLM | |
| 650 | 7 | |a 9Y8NXQ24VQ |2 NLM | |
| 700 | 1 | |a R, Nethish Kumaar |e verfasserin |4 aut | |
| 700 | 1 | |a Aswin, D |e verfasserin |4 aut | |
| 700 | 1 | |a Nair, Sreeja C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Therapeutic delivery |d 2010 |g 14(2023), 11 vom: 01. Nov., Seite 705-720 |w (DE-627)NLM203937082 |x 2041-6008 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2023 |g number:11 |g day:01 |g month:11 |g pages:705-720 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4155/tde-2023-0044 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2023 |e 11 |b 01 |c 11 |h 705-720 | ||